Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07300475 · ClinicalTrials.gov registry record · Phase 1

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

A Phase 1 study, sponsored by Washington University School of Medicine.

Not yet
Registry status
Phase 1
Development phase
30
Enrollment target

NCT07300475: Clinical Trial Phase 1 study, sponsored by Washington University School of Medicine.

NCT07300475 is a Phase 1 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07300475, a Phase 1 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.

NOT YET RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine (PCV) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative breast cancer undergoing neoadjuvant chemoimmunotherapy.

Primary Outcome

Treatment-emergent adverse events (TEAEs) will be assessed via CTCAE v6.

Interventions

  • DRUG Pembrolizumab
  • DRUG Cyclophosphamide
  • DRUG Carboplatin
  • DRUG Doxorubicin
  • DRUG Paclitaxel

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2026-08-01
Est. Completion 2035-04-30
Phase Phase 1
Washington University School of Medicine

1,502 total trials

What is known before NCT07300475 opens enrollment

NCT07300475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT07300475 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07300475 about?

NCT07300475 is a clinical study titled "Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients". This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine (PCV) strategy with or without CD8-selective IL-2 mutein fusion protein in patients with triple negative breast cancer undergoing neoadjuvant chemoimmunotherapy.

What is the current status of trial NCT07300475?

This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-08-01. Estimated completion is 2035-04-30.

What interventions are being tested in trial NCT07300475?

The interventions under investigation include: Pembrolizumab (DRUG), Cyclophosphamide (DRUG), Carboplatin (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG).

Who is sponsoring clinical trial NCT07300475?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT07300475's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07300475, the US trial registry maintained by the National Library of Medicine. NCT07300475 (small enrollment · none site footprint · not yet recruiting) retrieved and formatted by PlainTrial, see methodology.